An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Gataparsen (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 12 Aug 2008 The anticipated start date for this trial is now Aug 2008 according to clinicaltrials.gov record.
- 17 Mar 2008 Start date (Mar 2008) updated from ClinicalTrials.gov.
- 15 Jan 2007 New trial record.